ÌÇÐÄÆƽâ°æ

Distribution of Celltrion's revenue in 3rd quarter of 2024, by product

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

November 2024

Region

South Korea

Survey time period

Q3 2024

Supplementary notes

Values may not add up to 100 percent due to rounding.

* Includes Bevacizumab, Yuflyma, Zymfentra, Remsima SC, Herzuma, Truxima, Remsima IV/Inflectra, and Steqeyma.

Citation formats

Distribution of Celltrion's revenue Q3 2024, by product

Published by A. Minhas, Feb 19, 2025

During the third quarter of 2024, almost ** percent of Celltrion's revenue stemmed from its bioproducts, most notably Remsima IV, an anti-inflammatory used to treat several immune system conditions such as Crohn's disease.

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

10

Other regions

10

Related statistics

10

Further Content: You might find this interesting as well

Topics

Pharmaceutical market in the PhilippinesInsurance industry in the PhilippinesHealthcare in the Philippines Manufacturing in the PhilippinesForeign direct investment (FDI) into the Philippines
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.